Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation

被引：6

作者：

Baber U. ^{[1
]}

Van Der Zee S. ^{[1
]}

Fuster V. ^{[1
]}

机构：

[1] Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029

来源：

Current Cardiology Reports | 2010年 / 12卷 / 2期

关键词：

Anticoagulation; Atrial fibrillation; Mechanical heart valves;

D O I：

10.1007/s11886-010-0085-x

中图分类号：

学科分类号：

摘要：

Surgical replacement of a native valve with a biological or mechanical prosthesis is the definitive treatment for many forms of advanced valvular heart disease. Mechanical heart valves are less prone to structural deterioration compared with bioprostheses, but require chronic oral anticoagulation to prevent thromboembolic events. Thromboembolic risk varies based on patientrelated risk factors, including atrial fibrillation, advanced age, low ejection fraction, and hypercoagulability. Other important correlates of high thromboembolic risk include valve design, valve position, anticoagulation variability, and time from surgery. Clinical management is further complicated when antithrombotics may need to be interrupted or altered during surgery or pregnancy. At present, vitamin K antagonists are the only approved agents for thromboprophylaxis but are limited because of a narrow therapeutic window and requirement for frequent monitoring. Novel anticoagulants, including inhibitors of factor IIa and Xa, are currently being evaluated and may emerge as alternatives to vitamin K antagonists. © Springer Science+Business Media, LLC 2010.

引用

页码：133 / 139

页数：6

共 45 条

[1]

Carapetis J.R., Currie B.J., Mathews J.D., Cumulative incidence of rheumatic fever in an endemic region: A guide to the susceptibility of the population?, Epidemiol Infect, 124, pp. 239-244, (2000)

[2]

Cannegieter S.C., Rosendaal F.R., Briet E., Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses, Circulation, 89, pp. 635-641, (1994)

[3]

Butchart E.G., Lewis P.A., Kulatilake E.N., Breckenridge I.M., Anticoagulation variability between centres: Implications for comparative prosthetic valve assessment, Eur J Cardiothorac Surg, 2, pp. 72-81, (1988)

[4]

Yoganathan A.P., He Z., Casey Jones S., Fluid mechanics of heart valves, Annu Rev Biomed Eng, 6, pp. 331-362, (2004)

[5]

Butany J., Ahluwalia M.S., Munroe C., Fayet C., Ahn C., Blit P., Kepron C., Cusimano R.J., Leask R.L., Mechanical heart valve prostheses - Identification and evaluation, Cardiovascular Pathology, 12, 1, pp. 1-22, (2003)

[6]

Kulik A., Rubens F.D., Wells P.S., Kearon C., Mesana T.G., Van Berkom J., Lam B.-K., Early postoperative anticoagulation after mechanical valve replacement: A systematic review, Annals of Thoracic Surgery, 81, 2, pp. 770-781, (2006)

[7]

Bonow R.O., Carabello B.A., Chatterjee K., Et al., Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American heart association task force on Practice Guidelines, Circulation, 118, (2008)

[8]

Vahanian A., Baumgartner H., Bax J., Et al., Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European society of cardiology, Eur Heart J, 28, pp. 230-268, (2007)

[9]

Fanikos J., Tsilimingras K., Kucher N., Et al., Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation, Am J Cardiol, 93, pp. 247-250, (2004)

[10]

Montalescot G., Polle V., Collet J.P., Leprince P., Bellanger A., Gandjbakhch I., Thomas D., Low molecular weight heparin after mechanical heart valve replacement, Circulation, 101, 10, pp. 1083-1086, (2000)

← 1 2 3 4 5 →